eculizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
humanized origin	4969	219685-50-4

Description:

Molecule	Description
Synonyms: eculizumab soliris h5G1.1 h5G1.1VHC+h5G1.1VLC	a recombinant humanized monoclonal IgG2/4k antibody produced by murine myeloma cell culture, specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9 Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

eculizumab
soliris
h5G1.1
h5G1.1VHC+h5G1.1VLC

a recombinant humanized monoclonal IgG2/4k antibody produced by murine myeloma cell culture, specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
64	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company
June 20, 2007	EMA
March 16, 2007	FDA	ALEXION PHARM
April 16, 2010	PMDA	Alexion Pharma

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Haemolysis	504.65	18.00	140	13203	6628	63469051
Haemoglobin decreased	443.94	18.00	311	13032	145174	63330505
Blood lactate dehydrogenase increased	315.99	18.00	134	13209	22982	63452697
Thrombotic microangiopathy	271.97	18.00	97	13246	10464	63465215
Haemoglobinuria	189.32	18.00	35	13308	240	63475439
Meningococcal sepsis	158.49	18.00	23	13320	18	63475661
Platelet count decreased	151.04	18.00	152	13191	115970	63359709
Exposure during pregnancy	133.84	18.00	164	13179	155383	63320296
Suspected COVID-19	124.35	18.00	38	13305	2524	63473155
Chromaturia	111.07	18.00	59	13284	16658	63459021
Breakthrough haemolysis	96.44	18.00	14	13329	11	63475668
Meningococcal bacteraemia	92.16	18.00	13	13330	6	63475673
Renal transplant failure	91.43	18.00	23	13320	739	63474940
Reticulocyte count increased	90.67	18.00	24	13319	946	63474733
Extravascular haemolysis	88.24	18.00	16	13327	97	63475582
Incorrect dose administered	84.35	18.00	82	13261	59886	63415793
Aplastic anaemia	81.67	18.00	40	13303	9529	63466150
Renal impairment	77.23	18.00	94	13249	88261	63387418
Transfusion	69.41	18.00	42	13301	15175	63460504
Inappropriate schedule of product administration	68.15	18.00	96	13247	103869	63371810
Haptoglobin decreased	67.48	18.00	18	13325	731	63474948
Arteriovenous fistula occlusion	63.66	18.00	15	13328	364	63475315
Off label use	61.64	18.00	292	13051	674170	62801509
Gonorrhoea	61.43	18.00	12	13331	114	63475565
Poor venous access	60.30	18.00	38	13305	14747	63460932
Polyomavirus-associated nephropathy	59.23	18.00	20	13323	1828	63473851
Headache	59.18	18.00	276	13067	632965	62842714
Meningitis meningococcal	57.78	18.00	11	13332	90	63475589
Blue toe syndrome	57.46	18.00	14	13329	393	63475286
Cytomegalovirus infection	57.18	18.00	42	13301	20910	63454769
Proteinuria	53.65	18.00	39	13304	19106	63456573
Blood lactate dehydrogenase abnormal	53.46	18.00	13	13330	362	63475317
Blood creatinine increased	52.99	18.00	78	13265	87766	63387913
Myasthenia gravis crisis	49.44	18.00	13	13330	499	63475180
Dyspnoea exertional	49.20	18.00	62	13281	60240	63415439
Condition aggravated	48.83	18.00	190	13153	402027	63073652
Nephrectomy	47.07	18.00	16	13327	1492	63474187
Haemoglobin abnormal	45.61	18.00	22	13321	5066	63470613
Total complement activity decreased	44.81	18.00	6	13337	0	63475679
Gonococcal infection	44.81	18.00	6	13337	0	63475679
Drug intolerance	44.72	18.00	6	13337	308655	63167024
Platelet count abnormal	44.25	18.00	19	13324	3345	63472334
Anaemia	42.64	18.00	147	13196	293283	63182396
Transplant rejection	42.20	18.00	27	13316	10753	63464926
Plasmapheresis	40.93	18.00	10	13333	284	63475395
Atypical haemolytic uraemic syndrome	40.39	18.00	12	13331	723	63474956
Cervicitis	40.10	18.00	11	13332	497	63475182
Jaundice	39.24	18.00	39	13304	29212	63446467
Sepsis	39.09	18.00	94	13249	153029	63322650
Bacteraemia	39.03	18.00	31	13312	17317	63458362
Pre-eclampsia	38.56	18.00	24	13319	9109	63466570
Iron overload	38.12	18.00	12	13331	879	63474800
Pneumonia bacterial	37.78	18.00	24	13319	9441	63466238
Total complement activity increased	37.34	18.00	5	13338	0	63475679
Renal transplant	36.73	18.00	13	13330	1367	63474312
Drug hypersensitivity	36.65	18.00	10	13333	310677	63165002
SARS-CoV-2 test positive	36.13	18.00	22	13321	8034	63467645
Cytomegalovirus gastrointestinal infection	35.42	18.00	9	13334	301	63475378
Fatigue	35.04	18.00	311	13032	887717	62587962
Meningococcal infection	34.11	18.00	7	13336	87	63475592
Graft loss	33.77	18.00	9	13334	364	63475315
Haematocrit decreased	32.96	18.00	41	13302	39299	63436380
Premature delivery	32.78	18.00	36	13307	30245	63445434
Product use issue	32.61	18.00	4	13339	220516	63255163
Graft ischaemia	32.22	18.00	6	13337	43	63475636
Toxicity to various agents	31.01	18.00	7	13336	247243	63228436
Thrombosis	30.04	18.00	51	13292	64704	63410975
Waterhouse-Friderichsen syndrome	29.87	18.00	4	13339	0	63475679
Intravascular haemolysis	29.57	18.00	8	13335	343	63475336
Quality of life decreased	29.47	18.00	20	13323	8783	63466896
Multiple organ dysfunction syndrome	29.43	18.00	47	13296	56705	63418974
Hospitalisation	29.38	18.00	59	13284	85022	63390657
Swelling	28.69	18.00	11	13332	275367	63200312
Alopecia	28.36	18.00	18	13325	337518	63138161
Muscle strain	28.18	18.00	19	13324	8255	63467424
Babesiosis	27.91	18.00	7	13336	222	63475457
Rash	27.85	18.00	47	13296	560824	62914855
Bone marrow transplant	27.66	18.00	9	13334	733	63474946
Glossodynia	27.05	18.00	3	13340	178873	63296806
Renal pain	27.00	18.00	17	13326	6582	63469097
Haemolytic anaemia	26.95	18.00	20	13323	10105	63465574
SARS-CoV-2 test negative	26.78	18.00	8	13335	491	63475188
Pyrexia	26.36	18.00	179	13164	470299	63005380
Gastroenteritis	26.03	18.00	30	13313	26560	63449119
Delayed engraftment	26.02	18.00	6	13337	132	63475547
Complement factor abnormal	25.83	18.00	4	13339	7	63475672
Haptoglobin increased	25.74	18.00	5	13338	46	63475633
Device related infection	25.65	18.00	28	13315	23364	63452315
Joint swelling	25.49	18.00	19	13324	327647	63148032
Maternal exposure during breast feeding	25.46	18.00	14	13329	4227	63471452
Therapeutic product effect decreased	25.18	18.00	5	13338	193182	63282497
Graft thrombosis	24.96	18.00	6	13337	159	63475520
Arthritis bacterial	24.83	18.00	16	13327	6447	63469232
Abdominal discomfort	24.46	18.00	19	13324	320866	63154813
Reperfusion injury	24.09	18.00	5	13338	66	63475613
Blood product transfusion dependent	23.93	18.00	6	13337	190	63475489
Thrombocytopenia	23.91	18.00	78	13265	151079	63324600
Polyomavirus viraemia	23.75	18.00	8	13335	726	63474953
Budd-Chiari syndrome	23.68	18.00	5	13338	72	63475607
Small cell lung cancer recurrent	23.44	18.00	4	13339	16	63475663
Viral infection	23.43	18.00	33	13310	35630	63440049
Meningitis	23.30	18.00	16	13327	7161	63468518
Platelet transfusion	23.01	18.00	8	13335	798	63474881
Cytopenia	22.46	18.00	19	13324	11582	63464097
Treatment failure	22.36	18.00	7	13336	199036	63276643
Pain	21.96	18.00	81	13262	740547	62735132
Complement factor C3 decreased	21.44	18.00	6	13337	292	63475387
Dysphagia	21.11	18.00	53	13290	88532	63387147
Escherichia bacteraemia	21.08	18.00	12	13331	3871	63471808
Systemic lupus erythematosus	20.69	18.00	9	13334	208909	63266770
Serum ferritin increased	20.59	18.00	14	13329	6168	63469511
Abdominal pain	20.36	18.00	118	13225	293338	63182341
Complications of transplanted kidney	20.04	18.00	10	13333	2476	63473203
Myelodysplastic syndrome	20.03	18.00	21	13322	16733	63458946
Pregnancy	19.77	18.00	31	13312	36805	63438874
Hepatic enzyme increased	19.59	18.00	9	13334	202319	63273360
Ocular icterus	19.05	18.00	11	13332	3645	63472034
Uterine atony	18.84	18.00	5	13338	199	63475480
Red blood cell count decreased	18.83	18.00	32	13311	40613	63435066
Mucormycosis	18.69	18.00	10	13333	2861	63472818
Haematocrit abnormal	18.57	18.00	7	13336	880	63474799
Gastrointestinal mucormycosis	18.16	18.00	5	13338	229	63475450
Foetal growth restriction	18.07	18.00	14	13329	7539	63468140

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Haemolysis	417.97	20.01	133	9203	7961	34939634
Haemoglobin decreased	213.61	20.01	208	9128	120564	34827031
Haemoglobinuria	213.49	20.01	46	9290	569	34947026
Blood lactate dehydrogenase increased	208.37	20.01	108	9228	22882	34924713
Thrombotic microangiopathy	193.60	20.01	81	9255	10549	34937046
Breakthrough haemolysis	93.09	20.01	14	9322	11	34947584
Chromaturia	92.23	20.01	54	9282	14466	34933129
Extravascular haemolysis	87.99	20.01	14	9322	22	34947573
Haptoglobin decreased	82.94	20.01	21	9315	541	34947054
Fatigue	77.18	20.01	245	9091	370408	34577187
Transfusion	76.73	20.01	40	9296	8545	34939050
Meningococcal sepsis	74.98	20.01	12	9324	20	34947575
Poor venous access	73.09	20.01	33	9303	5150	34942445
Incorrect dose administered	69.84	20.01	69	9267	40446	34907149
Reticulocyte count increased	68.02	20.01	18	9318	554	34947041
Suspected COVID-19	66.51	20.01	21	9315	1218	34946377
Meningococcal bacteraemia	61.75	20.01	9	9327	4	34947591
End stage renal disease	61.71	20.01	35	9301	8826	34938769
Myasthenia gravis crisis	57.14	20.01	16	9320	611	34946984
Platelet count decreased	55.75	20.01	108	9228	119609	34827986
SARS-CoV-2 test positive	51.18	20.01	27	9309	5906	34941689
Polyomavirus viraemia	50.66	20.01	16	9320	929	34946666
Haemoglobin abnormal	46.28	20.01	22	9314	3858	34943737
Meningococcal infection	44.82	20.01	7	9329	9	34947586
Staphylococcal mediastinitis	42.13	20.01	8	9328	49	34947546
Headache	39.12	20.01	130	9206	200505	34747090
Complement factor increased	38.73	20.01	6	9330	7	34947588
Renal impairment	37.69	20.01	80	9256	94433	34853162
Cytomegalovirus oesophagitis	37.53	20.01	11	9325	495	34947100
Bone marrow transplant	36.95	20.01	13	9323	1055	34946540
Jaundice	36.85	20.01	44	9292	31838	34915757
Drug interaction	36.33	20.01	8	9328	225938	34721657
Device related infection	34.69	20.01	32	9304	17205	34930390
Off label use	34.49	20.01	210	9126	419314	34528281
C3 glomerulopathy	34.02	20.01	7	9329	68	34947527
Total complement activity decreased	33.79	20.01	5	9331	3	34947592
Aplastic anaemia	32.01	20.01	24	9312	9692	34937903
Condition aggravated	31.79	20.01	118	9218	192078	34755517
Haematocrit decreased	31.68	20.01	41	9295	32175	34915420
Complement factor C3 decreased	31.16	20.01	6	9330	40	34947555
Quality of life decreased	31.12	20.01	17	9319	3984	34943611
Blood product transfusion dependent	30.95	20.01	9	9327	394	34947201
Epstein-Barr viraemia	30.76	20.01	12	9324	1300	34946295
Inappropriate schedule of product administration	29.91	20.01	57	9279	62239	34885356
Cholelithiasis	29.19	20.01	32	9304	21116	34926479
Endoscopy upper gastrointestinal tract abnormal	29.18	20.01	6	9330	58	34947537
Transplant rejection	28.59	20.01	23	9313	10288	34937307
Disseminated varicella zoster virus infection	28.38	20.01	8	9328	313	34947282
Encephalitis viral	28.11	20.01	11	9325	1201	34946394
Infection	27.45	20.01	69	9267	90846	34856749
Polyomavirus-associated nephropathy	26.26	20.01	15	9321	3829	34943766
Viral sepsis	25.63	20.01	6	9330	110	34947485
Intravascular haemolysis	25.43	20.01	8	9328	458	34947137
Multiple organ dysfunction syndrome	24.05	20.01	59	9277	76507	34871088
Graft loss	24.02	20.01	9	9327	874	34946721
Dyspnoea exertional	23.80	20.01	42	9294	43237	34904358
Brain abscess	23.54	20.01	13	9323	3112	34944483
Myelodysplastic syndrome	23.00	20.01	27	9309	19181	34928414
Abdominal pain	22.62	20.01	95	9241	163523	34784072
Nasopharyngitis	22.06	20.01	54	9282	69914	34877681
Graft versus host disease	22.00	20.01	20	9316	10549	34937046
Haptoglobin abnormal	21.69	20.01	3	9333	0	34947595
Platelet count abnormal	21.58	20.01	12	9324	2910	34944685
Renal tubular atrophy	21.55	20.01	9	9327	1163	34946432
Meningitis meningococcal	21.14	20.01	4	9332	24	34947571
Blood creatinine abnormal	20.96	20.01	11	9325	2379	34945216

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Haemolysis	488.36	16.12	154	14950	12658	79716626
Thrombotic microangiopathy	394.07	16.12	147	14957	20022	79709262
Haemoglobin decreased	279.51	16.12	272	14832	221847	79507437
Blood lactate dehydrogenase increased	238.75	16.12	126	14978	39044	79690240
Meningococcal sepsis	173.19	16.12	27	15077	59	79729225
Incorrect dose administered	148.37	16.12	120	14984	76510	79652774
Meningococcal bacteraemia	137.20	16.12	19	15085	8	79729276
Off label use	131.10	16.12	422	14682	906793	78822491
Haptoglobin decreased	118.09	16.12	31	15073	1316	79727968
Extravascular haemolysis	115.76	16.12	21	15083	144	79729140
Haemoglobinuria	113.42	16.12	27	15077	764	79728520
Platelet count decreased	107.82	16.12	157	14947	194507	79534777
Renal impairment	101.87	16.12	137	14967	157646	79571638
Reticulocyte count increased	98.39	16.12	27	15077	1359	79727925
Breakthrough haemolysis	91.02	16.12	13	15091	10	79729274
Suspected COVID-19	88.31	16.12	30	15074	3103	79726181
Chromaturia	85.66	16.12	56	15048	25690	79703594
Polyomavirus-associated nephropathy	84.83	16.12	34	15070	5593	79723691
Inappropriate schedule of product administration	84.66	16.12	115	14989	133513	79595771
Polyomavirus viraemia	79.71	16.12	24	15080	1683	79727601
Exposure during pregnancy	79.71	16.12	97	15007	101035	79628249
End stage renal disease	79.21	16.12	41	15063	12179	79717105
Renal transplant failure	77.09	16.12	24	15080	1883	79727401
Myasthenia gravis crisis	71.31	16.12	20	15084	1091	79728193
Meningitis meningococcal	70.01	16.12	13	15091	103	79729181
Atypical haemolytic uraemic syndrome	63.62	16.12	18	15086	1014	79728270
Meningococcal infection	63.36	16.12	12	15092	107	79729177
Toxicity to various agents	61.18	16.12	5	15099	421535	79307749
Gonorrhoea	60.91	16.12	13	15091	221	79729063
Arteriovenous fistula occlusion	59.60	16.12	15	15089	537	79728747
Haemoglobin abnormal	58.55	16.12	28	15076	7026	79722258
SARS-CoV-2 test positive	58.33	16.12	33	15071	11683	79717601
Condition aggravated	57.85	16.12	217	14887	500907	79228377
Poor venous access	56.79	16.12	38	15066	18111	79711173
Transplant rejection	56.77	16.12	39	15065	19398	79709886
Cytomegalovirus infection	54.85	16.12	53	15051	42591	79686693
Graft loss	54.52	16.12	16	15088	1027	79728257
Blue toe syndrome	53.72	16.12	14	15090	577	79728707
Complement factor increased	53.66	16.12	8	15096	11	79729273
Proteinuria	52.72	16.12	46	15058	32456	79696828
Drug interaction	52.52	16.12	8	15096	415175	79314109
Multiple organ dysfunction syndrome	49.85	16.12	85	15019	120161	79609123
Cervicitis	48.85	16.12	11	15093	242	79729042
Blood lactate dehydrogenase abnormal	47.90	16.12	11	15093	265	79729019
Nephrectomy	47.13	16.12	17	15087	2098	79727186
Epstein-Barr viraemia	46.44	16.12	17	15087	2188	79727096
Staphylococcal mediastinitis	44.74	16.12	8	15096	50	79729234
C3 glomerulopathy	43.71	16.12	8	15096	58	79729226
Dyspnoea exertional	43.50	16.12	67	15037	87006	79642278
Gonococcal infection	42.69	16.12	8	15096	67	79729217
Transfusion	42.49	16.12	34	15070	21296	79707988
Aplastic anaemia	41.01	16.12	31	15073	17874	79711410
Bacteraemia	40.72	16.12	40	15064	32784	79696500
Jaundice	40.11	16.12	50	15054	53299	79675985
Complement factor C3 decreased	39.47	16.12	10	15094	368	79728916
Graft versus host disease	38.88	16.12	28	15076	14998	79714286
Total complement activity decreased	37.86	16.12	5	15099	0	79729284
Total complement activity increased	37.86	16.12	5	15099	0	79729284
Drug hypersensitivity	37.23	16.12	6	15098	298910	79430374
Waterhouse-Friderichsen syndrome	35.51	16.12	5	15099	3	79729281
Blood creatinine increased	34.80	16.12	85	15019	154972	79574312
Budd-Chiari syndrome	34	16.12	7	15097	99	79729185
Renal transplant	33.64	16.12	14	15090	2533	79726751
Graft ischaemia	33.35	16.12	6	15098	39	79729245
Sepsis	32.94	16.12	119	14985	269309	79459975
Cytomegalovirus oesophagitis	32.56	16.12	10	15094	750	79728534
Cytomegalovirus gastrointestinal infection	31.87	16.12	9	15095	503	79728781
Drug intolerance	31.37	16.12	6	15098	264113	79465171
Fatigue	31.20	16.12	290	14814	929437	78799847
Iron overload	30.67	16.12	12	15092	1852	79727432
Endoscopy upper gastrointestinal tract abnormal	30.54	16.12	6	15098	66	79729218
Pre-eclampsia	30.19	16.12	18	15086	7023	79722261
Bone marrow transplant	29.89	16.12	11	15093	1437	79727847
Adenovirus infection	29.63	16.12	19	15085	8428	79720856
Kidney fibrosis	29.24	16.12	14	15090	3521	79725763
Rheumatoid arthritis	28.80	16.12	3	15101	208467	79520817
Haemolytic anaemia	28.45	16.12	25	15079	17795	79711489
Intravascular haemolysis	27.59	16.12	9	15095	821	79728463
Renal pain	27.47	16.12	18	15086	8278	79721006
Gastroenteritis	27.32	16.12	33	15071	34049	79695235
Renal tubular atrophy	27.23	16.12	11	15093	1845	79727439
Encephalitis viral	26.91	16.12	12	15092	2567	79726717
Complications of transplanted kidney	26.58	16.12	16	15088	6350	79722934
Hypertension	26.20	16.12	128	14976	330864	79398420
Haemolytic uraemic syndrome	26.19	16.12	14	15090	4435	79724849
Premature delivery	26.17	16.12	27	15077	23440	79705844
Disseminated varicella zoster virus infection	25.73	16.12	8	15096	625	79728659
Haematocrit abnormal	25.59	16.12	10	15094	1538	79727746
Device related infection	25.55	16.12	32	15072	34262	79695022
Babesiosis	25.43	16.12	7	15097	356	79728928
Plasmapheresis	25.29	16.12	8	15096	661	79728623
Viral sepsis	25.19	16.12	6	15098	170	79729114
Myelodysplastic syndrome	23.74	16.12	29	15075	30272	79699012
Arthritis bacterial	23.53	16.12	17	15087	9149	79720135
Small cell lung cancer recurrent	22.65	16.12	4	15100	23	79729261
Delayed engraftment	22.18	16.12	6	15098	286	79728998
Brain abscess	22.16	16.12	13	15091	4923	79724361
Red blood cell schistocytes present	22.09	16.12	7	15097	582	79728702
Pain	21.77	16.12	65	15039	703737	79025547
Mean cell volume increased	21.77	16.12	14	15090	6239	79723045
Glomerulonephritis membranoproliferative	21.70	16.12	7	15097	616	79728668
Hypervolaemia	21.52	16.12	33	15071	42657	79686627
Product dose omission issue	21.48	16.12	10	15094	247527	79481757
Pruritus	21.37	16.12	26	15078	394622	79334662
Therapeutic product effect decreased	21.05	16.12	3	15101	163860	79565424
Muscle strain	20.69	16.12	16	15088	9539	79719745
Serum ferritin increased	20.26	16.12	16	15088	9831	79719453
Neisseria infection	20.14	16.12	5	15099	169	79729115
Haematocrit decreased	19.88	16.12	39	15065	61273	79668011
Platelet count abnormal	19.73	16.12	12	15092	4850	79724434
SARS-CoV-2 test negative	19.68	16.12	8	15096	1363	79727921
Reperfusion injury	19.43	16.12	5	15099	196	79729088
Complement factor abnormal	19.42	16.12	3	15101	6	79729278
Pneumonia bacterial	19.35	16.12	21	15083	19310	79709974
Haptoglobin increased	19.07	16.12	5	15099	211	79729073
Laboratory test abnormal	19.05	16.12	25	15079	28023	79701261
Thrombosis	18.74	16.12	46	15058	84054	79645230
Haptoglobin abnormal	17.89	16.12	3	15101	12	79729272
Cholelithiasis	17.69	16.12	34	15070	52630	79676654
Kidney transplant rejection	17.62	16.12	15	15089	10231	79719053
Syncope	17.61	16.12	6	15098	179443	79549841
Febrile neutropenia	17.60	16.12	11	15093	230988	79498296
Headache	17.55	16.12	195	14909	653577	79075707
Anaemia	17.53	16.12	144	14960	444871	79284413
Pericarditis constrictive	17.52	16.12	6	15098	636	79728648
Escherichia urinary tract infection	17.43	16.12	17	15087	13808	79715476
Septic shock	17.39	16.12	57	15047	122744	79606540
Malignant atrophic papulosis	17.34	16.12	3	15101	15	79729269
Viral infection	17.27	16.12	30	15074	42986	79686298
Neuropathy peripheral	17.22	16.12	3	15101	141302	79587982
Confusional state	17.16	16.12	21	15083	317976	79411308
Osteomyelitis chronic	16.97	16.12	6	15098	698	79728586
Depression	16.97	16.12	10	15094	216780	79512504
Rash	16.75	16.12	55	15049	578303	79150981
Complement factor C4 decreased	16.68	16.12	5	15099	345	79728939
Escherichia bacteraemia	16.46	16.12	12	15092	6550	79722734
Meningitis	16.42	16.12	14	15090	9568	79719716
Pseudomonas infection	16.36	16.12	20	15084	20883	79708401
Alopecia	16.31	16.12	12	15092	231343	79497941

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AA25	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Selective immunosuppressants
FDA EPC	N0000175575	Complement Inhibitor
MeSH PA	D051056	Complement Inactivating Agents
MeSH PA	D007155	Immunologic Factors
MeSH PA	D007166	Immunosuppressive Agents
FDA MoA	N0000175974	Complement Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Paroxysmal nocturnal hemoglobinuria	indication	1963002	DOID:0060284
Neuromyelitis optica	indication	25044007	DOID:8869
Refractory generalized myasthenia gravis	indication	230686005
Congenital hemolytic uremic syndrome	indication	444976001
Atypical hemolytic uremic syndrome	indication	789660001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Complement C5	Secreted	P01031	CO5_HUMAN	ANTIBODY BINDING				DRUG LABEL	DRUG LABEL

External reference:

ID	Source
D03940	KEGG_DRUG
4026032	VUID
N0000179786	NUI
4026032	VANDF
CHEMBL1201828	ChEMBL_ID
C481642	MESH_SUPPLEMENTAL_RECORD_UI
6884	IUPHAR_LIGAND_ID
DB01257	DRUGBANK_ID
591781	RXNORM
108542	MMSL
23533	MMSL
d06673	MMSL
012087	NDDF
426801002	SNOMEDCT_US
427429004	SNOMEDCT_US
C1541483	UMLSCUI
8231	INN_ID
A3ULP0F556	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
SOLIRIS	HUMAN PRESCRIPTION DRUG LABEL	1	25682-001	INJECTION, SOLUTION, CONCENTRATE	300 mg	INTRAVENOUS	BLA	29 sections
SOLIRIS	HUMAN PRESCRIPTION DRUG LABEL	1	25682-001	INJECTION, SOLUTION, CONCENTRATE	300 mg	INTRAVENOUS	BLA	29 sections